The action, to be published Monday in the Federal Register, comes as the agency puts increased focus on long-term safety of drugs that treat diabetes and obesity, and prevent cardiovascular events.
On Monday, FDA will withdraw approvals for 2 medications that had been used with statins to treat high levels of cholesterol. The pending decision was listed in documents ready for publication in the Federal Register and was first reported by Medscape.
The affected therapies, both sold by AbbVie, are niacin extended release (Niaspan) and fenofibric acid (Tripilix). The order will also affect the combination therapies Advicor, which combines niacin with lovastatin, and Simcor, which combines niacin with simvastatin.
This unusual step is a result of FDA’s increased attention to long-term safety effects of medications for diabetes, obesity, and to prevent heart disease. Documentation with the notice lists results from several trials, including those from ACCORD, AIM-HIGH, and the HPS2-THRIVE Collaboration Group. The agency said the evidence "no longer supports the conclusion that a drug-induced reduction in triglyceride leels and/or increase in HDL-cholesterol levels in statin-treated patients results in a reduction in the risk of cardiovascular events."
FDA’s pending withdrawal notice states that that agency asked AbbVie to voluntarily stop marketing Advicor and Simcor and the company agreed, waiving its right for a hearing.
“The agency has also determined that Advicor and Simcor were withdrawn from sale for reasons of safety and effectiveness, and FDA will not accept or approve abbreviated drug applications that reference Advicor and Simcor,” the notice states.
Niacin extended-release (Niaspan) received approval in 1997. Advicor was subsequently approved to treat hypercholesterolemia, both familial and nonfamilial, as well as mixed dyslipidemia for patients whose triglycerides or low-density lipoprotein (LDL) cholesterol levels remain high on less-intense therapy.
Simcor was approved in 2008 to treat total cholesterol levels, apolipoprotein B, triglycerides or to raise HDL or “good” cholesterol in patients with hypercholesterolemia and mixed dyslipidemia.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen